March 9, 2026
Tumor Tip of the Week 03-06-2026 Invasive Breast, Neoadjuvant, DCIS
03-06-2026 Invasive Breast, Neoadjuvant, DCIS
Scenario #1:
- Screening digital mammogram with CAD with 3D bilateral-Technique: The following mammographic views were obtained: bilateral CC and MLO views were obtained in 2D and 3D (Digital Breast Tomosynthesis) -calcifications left breast 3:00 BI-RADS 0
- Needle bx: Invasive ductal Carcinoma, G3, Her2+, ER-, PR-
- MRI: Clumped non mass enhancement lt entire upper outer breast measuring 6.4cm extending to chest wall. No lad
- Med Onc staged as cT1a cN0 cM0, treated with Neoadjuvant Taxol, Pertuzumab and Trastuzumab
- Bilateral Simple Mastectomy w/ SLN bx w/o reconstruction
Question: How would you assign the ypT category?
- ypT0
- ypTis
- ypTX
- ypT Blank
Answer: ypTis
Rationale: There was no residual invasive carcinoma, however there was 10mm of residual DCIS, Nuclear Grade III
Some other fields to consider:
| Field(s) | Result | Resources |
| yp Stage: | ypTis ypN1a (sn) cM0 | AJCC 8th Edition Chapter 48 |
| yp Grade H | H | Grade Manual v3.3 Note 3: Assign the highest grade from the resected primary tumor assessed after the completion of neoadjuvant therapy |
| Residual Cancer Burden (RBC) | 1 | *New SSDI 2026+ Only record the information from the CAP Protocol or synoptic pathology report-SSDI Manual v 3.3 |
| Residual Cancer Burden (RBC) Class | 1.205 | *New SSDI 2026+Only record the information from the CAP Protocol or synoptic pathology report-SSDI Manual v 3.3 |
| Method of Detection for Breast Primary (NCDB Custom Data Item) | 02 | *New Data Items required for cases with diagnosis year 2026+ [COC Facilities ONLY]-STORE 2026 |
